Inge Marie Svane

Research output

Research output per year 2003 2010 2011 2012 2013 2015 2016 2017 2018 2019 2019

• 140 Journal article
• 9 Review
• 5 Comment/debate
• 4 Book chapter
• 6 More
  • 3 Conference abstract in journal
  • 2 Letter
  • 1 Conference abstract for conference

Research output per year

Research output per year

Search results

• 2019

  Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

  Martinenaite, E., Ahmad, S. M., Bendtsen, S. K., Jørgensen, M. A., Weis-Banke, S. E., Svane, I. M. & Andersen, M. H., 2019, In: Cancer Immunology, Immunotherapy. 68, 11, p. 1901-1907 7 p.

  Research output: Contribution to journal › Review › peer-review

  • Arginase 100%
  • T-Lymphocyte Epitopes 92%
  • Tumor Microenvironment 79%
  • Vaccination 61%
  • T-Lymphocytes 35%
  2 Citations (Scopus)

• B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment

  Sørensen, A. L., Bjørn, M. E., Riley, C. H., Holmstrøm, M., Andersen, M. H., Svane, I. M., Mikkelsen, S. U., Skov, V., Kjaer, L., Hasselbalch, H. C. & Nielsen, C. H., 1 Oct 2019, In: European Journal of Haematology. p. 351-361 11 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • INCB018424 100%
  • Interferons 59%
  • B-Lymphocytes 49%
  • Phenotype 38%
  • Primary Myelofibrosis 26%
  5 Citations (Scopus)

• Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

  Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., Svane, I. M., Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B., Ghori, R., Ibrahim, N., Moreno, B. H. & Ribas, A., 1 Jun 2019, In: Nature Medicine. 25, 6, p. 941-946 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Trametinib 100%
  • Dabrafenib 92%
  • dabrafenib 74%
  • trametinib 74%
  • pembrolizumab 66%
  107 Citations (Scopus)

• Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs

  Draghi, A., Borch, T. H., Radic, H. D., Chamberlain, C. A., Gokuldass, A., Svane, I. M. & Donia, M., 1 Sept 2019, In: International Journal of Cancer.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • corticosteroids 100%
  • necrosis 75%
  • Tumor-Infiltrating Lymphocytes 70%
  • tumors 52%
  • Adrenal Cortex Hormones 44%
  16 Citations (Scopus)

• HER2 CAR-T cells eradicate uveal melanoma and T-cell therapy–resistant human melanoma in IL2 transgenic NOD/SCID IL2 receptor knockout mice

  Forsberg, E. M. V., Lindberg, M. F., Jespersen, H., Alsen, S., Bagge, R. O., Donia, M., Svane, I. M., Nilsson, O., Ny, L., Nilsson, L. M. & Nilsson, J. A., 2019, In: Cancer Research. 79, 5, p. 899-904 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Chimeric Antigen Receptors 100%
  • Uveal melanoma 98%
  • Interleukin-2 Receptors 86%
  • Knockout Mice 67%
  • Interleukin-2 66%
  27 Citations (Scopus)

• High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals

  Holmström, M. O., Ahmad, S. M., Klausen, U., Bendtsen, S. K., Martinenaite, E., Riley, C. H., Svane, I. M., Kjær, L., Skov, V., Ellervik, C., Pallisgaard, N., Hasselbalch, H. C. & Andersen, M. H., 2019, In: Blood Cancer Journal. 9, 2, 8.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Calreticulin 100%
  • Exons 59%
  • T-Lymphocytes 44%
  • Mutation 40%
  • Genes 28%
  14 Citations (Scopus)

  47 Downloads (Pure)

• Immunoprofiles of colorectal cancer from Lynch syndrome

  Walkowska, J., Kallemose, T., Jönsson, G., Jönsson, M., Andersen, O., Andersen, M. H., Svane, I. M., Langkilde, A., Nilbert, M. & Therkildsen, C., 2 Jan 2019, In: OncoImmunology. 8, 1, 9 p., e1515612.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Hereditary Nonpolyposis Colorectal Neoplasms 100%
  • Colorectal Neoplasms 60%
  • beta 2-Microglobulin 34%
  • Ligands 29%
  • Neoplasms 24%
  2 Citations (Scopus)

• MERTK Acts as a costimulatory receptor on human cd8 t cells

  Peeters, M. J. W., Dulkeviciute, D., Draghi, A., Ritter, C., Rahbech, A., Skadborg, S. K., Seremet, T., Simoes, A. M. C., Martinenaite, E., Halldorsdottir, H. R., Andersen, M. H., Olofsson, G. H., Svane, I. M., Rasmussen, L. J., Met, O., Becker, J. C., Donia, M., Desler, C. & Straten, P. T., 2019, In: Cancer Immunology Research. 7, 9, p. 1472-1484 13 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • c-Mer Tyrosine Kinase 100%
  • T-Lymphocytes 26%
  • Tumor-Infiltrating Lymphocytes 23%
  • Receptor Protein-Tyrosine Kinases 6%
  • Antigen-Presenting Cells 6%
  13 Citations (Scopus)

• Peripheral memory T cells specific for Arginase-1

  Martinenaite, E., Ahmad, S. M., Svane, I. M. & Andersen, M. H., 2019, In: Cellular and Molecular Immunology. 16, 8, p. 718-719 2 p.

  Research output: Contribution to journal › Comment/debate › Research › peer-review

  3 Citations (Scopus)

• Principles of adoptive T cell therapy in cancer

  Met, Ö., Jensen, K. M., Chamberlain, C. A., Donia, M. & Svane, I. M., 11 Jan 2019, In: Seminars in Immunopathology. 41, 1, p. 49–58

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Cell- and Tissue-Based Therapy 100%
  • T-Lymphocytes 65%
  • Neoplasms 34%
  • Tumor-Infiltrating Lymphocytes 33%
  • B-Lymphocytes 20%
  35 Citations (Scopus)

• Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

  Ascierto, P. A., Long, G. V., Robert, C., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Ny, L., & 8 othersArance, A., Svane, I. M., Schadendorf, D., Gogas, H., Saci, A., Jiang, J., Rizzo, J. & Atkinson, V., Feb 2019, In: JAMA Oncology. 5, 2, p. 187-194

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Nivolumab 100%
  • Dacarbazine 75%
  • Melanoma 60%
  • Survival 40%
  • Therapeutics 12%
  122 Citations (Scopus)

• T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients

  Viborg, N., Ramskov, S., Andersen, R. S., Sturm, T., Fugmann, T., Bentzen, A. K., Rafa, V. M., Straten, P. T., Svane, I. M., Met, Ö. & Hadrup, S. R., 2 Dec 2019, In: OncoImmunology. 8, 12, 11 p., 1663107.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • HLA-A*02:01 antigen 100%
  • Breast Neoplasms 69%
  • Antigens 69%
  • T-Lymphocytes 67%
  • Immunotherapy 57%
  3 Citations (Scopus)

  25 Downloads (Pure)

• The real-world impact of modern treatments on the survival of patients with metastatic melanoma

  Donia, M., Ellebaek, E., Øllegaard, T. H., Duval, L., Aaby, J. B., Hoejberg, L., Køhler, U. H., Schmidt, H., Bastholt, L. & Svane, I. M., 2019, In: European Journal of Cancer. 108, p. 25-32 8 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Melanoma 100%
  • Survival 66%
  • Confidence Intervals 35%
  • Population 29%
  • interleukin 2 inhibitor 26%
  20 Citations (Scopus)

• Tumour-reactive T cell subsets in the microenvironment of ovarian cancer

  Westergaard, M. C. W., Andersen, R., Chong, C., Kjeldsen, J. W., Pedersen, M., Friese, C., Hasselager, T., Lajer, H., Coukos, G., Bassani-Sternberg, M., Donia, M. & Svane, I. M., 2019, In: British Journal of Cancer. 120, 4, p. 424-434 11 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • T-Lymphocyte Subsets 84%
  • Ovarian Neoplasms 71%
  • Neoplasms 25%
  • Antigens 18%
  22 Citations (Scopus)

  11 Downloads (Pure)
• 2018

  Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study

  Pedersen, M., Westergaard, M. C. W., Milne, K., Nielsen, M., Borch, T. H., Poulsen, L. G., Hendel, H. W., Kennedy, M., Briggs, G., Ledoux, S., Nøttrup, T. J., Andersen, P., Hasselager, T., Met, Ö., Nelson, B. H., Donia, M. & Svane, I. M., 2 Dec 2018, In: OncoImmunology. 7, 12, 12 p., e1502905.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • Cell- and Tissue-Based Therapy 74%
  • Ovarian Neoplasms 71%
  • Interleukin-2 17%
  • Platinum 10%
  30 Citations (Scopus)

• Cancer immunotherapy in patients with brain metastases

  Caponnetto, S., Draghi, A., Borch, T. H., Nuti, M., Cortesi, E., Svane, I. M. & Donia, M., 2018, In: Cancer Immunology, Immunotherapy. 67, 5, p. 703-711 9 p.

  Research output: Contribution to journal › Review › peer-review

  • Immunotherapy 100%
  • Neoplasm Metastasis 70%
  • Brain 55%
  • Neoplasms 36%
  • Clinical Trials 29%
  7 Citations (Scopus)

• Cancerimmunterapi

  Translated title of the contribution: Cancer immunotherapyKjeldsen, J. W., Donia, M. & Svane, I. M., 21 May 2018, In: Ugeskrift for Laeger. 180, 5 p., V09170691.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Immunotherapy 100%
  • pembrolizumab 39%
  • Ipilimumab 39%
  • Nivolumab 38%
  • Neoplasms 36%
  1 Citation (Scopus)

• Checkpoint inhibitors in breast cancer - current status

  Polk, A., Svane, I-M., Andersson, M. & Nielsen, D., Feb 2018, In: Cancer Treatment Reviews. 63, p. 122-134

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Triple Negative Breast Neoplasms 100%
  • Breast Neoplasms 79%
  • Biomarkers 53%
  • Antineoplastic Agents 39%
  • Progression-Free Survival 37%
  55 Citations (Scopus)

• Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

  Kverneland, A. H., Enevold, C., Donia, M., Bastholt, L., Svane, I. M. & Nielsen, C. H., 4 May 2018, In: OncoImmunology. 7, 5, p. e1424674 6 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Ipilimumab 100%
  • Anti-Idiotypic Antibodies 60%
  • Melanoma 59%
  • Survival 39%
  • Pharmaceutical Preparations 29%
  23 Citations (Scopus)

  39 Downloads (Pure)

• Durable clinical responses and long-term follow-up of stage III-IV non-small-cell lung cancer (NSCLC) patients treated with IDO peptide vaccine in a phase i study-a brief research report

  Kjeldsen, J. W., Iversen, T. Z., Engell-Noerregaard, L., Mellemgaard, A., Andersen, M. H. & Svane, I. M., 2018, In: Frontiers in Immunology. 9, SEP, 6 p., 2145.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Indoleamine-Pyrrole 2,3,-Dioxygenase 100%
  • Subunit Vaccines 89%
  • Non-Small Cell Lung Carcinoma 66%
  • Vaccination 32%
  • Vaccines 18%
  16 Citations (Scopus)

  32 Downloads (Pure)

• Frequent adaptive immune responses against arginase-1

  Martinenaite, E., Mortensen, R. E. J., Hansen, M., Orebo Holmström, M., Munir Ahmad, S., Grønne Dahlager Jørgensen, N., Met, Ö., Donia, M., Svane, I. M. & Andersen, M. H., 4 Mar 2018, In: OncoImmunology. 7, 3, 9 p., e1404215.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Arginase 100%
  • Adaptive Immunity 78%
  • T-Lymphocytes 21%
  • Peptide Library 16%
  • Myeloid-Derived Suppressor Cells 15%
  15 Citations (Scopus)

• Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

  Jensen, C., Madsen, D. H., Hansen, M., Schmidt, H., Svane, I. M., Karsdal, M. A. & Willumsen, N., 19 Dec 2018, In: Journal for ImmunoTherapy of Cancer. 6, 1, p. 1-10 10 p., 152.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Ipilimumab 100%
  • Extracellular Matrix 80%
  • Melanoma 78%
  • Biomarkers 61%
  • Collagen Type III 57%
  18 Citations (Scopus)

  47 Downloads (Pure)

• Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies

  Klausen, U., Holmberg, S., Holmstrom, M. O., Jorgensen, N. G. D., Grauslund, J. H., Svane, I. M. & Andersen, M. H., 1 Oct 2018, In: Frontiers in Immunology. 9, 8 p., 2264.

  Research output: Contribution to journal › Review › peer-review

  • Subunit Vaccines 100%
  • Hematologic Neoplasms 83%
  • Vaccination 52%
  • Antigens 52%
  • Tumor Microenvironment 51%
  13 Citations (Scopus)

  54 Downloads (Pure)

• Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations

  Rius, C., Attaf, M., Tungatt, K., Bianchi, V., Legut, M., Bovay, A., Donia, M., Thor Straten, P., Peakman, M., Svane, I. M., Ott, S., Connor, T., Szomolay, B., Dolton, G. & Sewell, A. K., 1 Apr 2018, In: The Journal of Immunology. 200, 7, p. 2263-2279

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Histocompatibility Antigens Class I 100%
  • Antigens 53%
  • T-Lymphocytes 52%
  • Peptides 44%
  • Population 33%
  35 Citations (Scopus)

  39 Downloads (Pure)

• Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes

  Kjaer, L., Holmström, M. O., Cordua, S., Andersen, M. H., Svane, I. M., Thomassen, M., Kruse, T. A., Pallisgaard, N., Skov, V. & Hasselbalch, H. C., 10 Aug 2018, In: Leukemia and Lymphoma. 59, 4, p. 973-977 5 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  9 Citations (Scopus)

• Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response

  Holmström, M. O., Riley, C. H., Skov, V., Svane, I. M., Hasselbalch, H. C. & Andersen, M. H., 3 Jun 2018, In: OncoImmunology. 7, 6, e1433521.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Ligands 100%
  • T-Lymphocytes 87%
  • Neoplasms 45%
  • Epitopes 24%
  • Immunity 11%
  17 Citations (Scopus)

• T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy

  Andersen, R., Westergaard, M. C. W., Kjeldsen, J. W., Müller, A., Pedersen, N. W., Hadrup, S. R., Met, Ö., Seliger, B., Kromann-Andersen, B., Hasselager, T., Donia, M. & Svane, I. M., Feb 2018, In: Cancer Immunology Research. 6, 2, p. 222-235 14 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Renal Cell Carcinoma 100%
  • Cell- and Tissue-Based Therapy 98%
  • T-Lymphocytes 64%
  • Melanoma 54%
  • Neoplasms 24%
  31 Citations (Scopus)

• T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression

  Andersen, R., Borch, T. H., Draghi, A., Gokuldass, A., Rana, M. A. H., Pedersen, M., Nielsen, M., Kongsted, P., Kjeldsen, J. W., Westergaard, M. C. W., Radic, H. D., Chamberlain, C. A., Hölmich, L. R., Hendel, H. W., Larsen, M. S., Met, Ö., Svane, I. M. & Donia, M., 1 Jul 2018, In: Annals of Oncology. 29, 7, p. 1575-1581 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • Melanoma 98%
  • T-Lymphocytes 73%
  • Neoplasms 38%
  • Programmed Cell Death 1 Receptor 14%
  21 Citations (Scopus)

• The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

  Holmstrom, M. O., Martinenaite, E., Ahmad, S. M., Met, O., Friese, C., Kjaer, L., Riley, C. H., Straten, P. T., Svane, I. M., Hasselbalch, H. C. & Andersen, M. H., 1 Feb 2018, In: Leukemia. 32, 2, p. 429-437

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Calreticulin 100%
  • Exons 59%
  • T-Lymphocytes 44%
  • Mutation 40%
  • Neoplasms 23%
  47 Citations (Scopus)

• The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

  Ahmad, S. M., Martinenaite, E., Holmström, M., Jørgensen, M. A., Met, Ö., Nastasi, C., Klausen, U., Donia, M., Pedersen, L. M., Munksgaard, L., Ødum, N., Woetmann, A., Svane, I. M. & Andersen, M. H., 1 Feb 2018, In: OncoImmunology. 7, 2, 10 p., e1390641.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • T-Lymphocytes 100%
  • Epitopes 46%
  • Neoplasms 28%
  • B7 Antigens 26%
  • Therapeutics 26%
  18 Citations (Scopus)
• 2017

  Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

  Donia, M., Harbst, K., van Buuren, M., Kvistborg, P., Lindberg, M. F., Andersen, R., Idorn, M., Munir Ahmad, S., Ellebæk, E., Mueller, A., Fagone, P., Nicoletti, F., Libra, M., Lauss, M., Hadrup, S. R., Schmidt, H., Andersen, M. H., Thor Straten, P., Nilsson, J. A., Schumacher, T. N., & 3 othersSeliger, B., Jönsson, G. & Svane, I. M., 1 Sept 2017, In: Cancer Research. 77, 17, p. 4562-4566 5 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Antigens 100%
  • Immunotherapy 51%
  • Neoplasms 50%
  • Recurrence 45%
  • Antigen Presentation 42%
  27 Citations (Scopus)

• Cancer immunotherapy in patients with preexisting autoimmune disorders

  Donia, M., Pedersen, M. & Svane, I. M., 1 Apr 2017, In: Seminars in Immunopathology. 39, 3, p. 333-337 5 p.

  Research output: Contribution to journal › Review › peer-review

  • Preexisting Condition Coverage 100%
  • Immunotherapy 73%
  • Neoplasms 26%
  • Clinical Trials 21%
  • Blocking Antibodies 20%
  25 Citations (Scopus)

• Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer

  Kongsted, P., Svane, I. M., Lindberg, H. & Sengeløv, L., 1 Apr 2017, In: Clinical Genitourinary Cancer. 15, 2, p. e281-e287

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Docetaxel 100%
  • Castration 98%
  • Prostatic Neoplasms 70%
  • Survival 26%
  • Prostate-Specific Antigen 21%
  4 Citations (Scopus)

• Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model

  Jespersen, H., Lindberg, M. F., Donia, M., Söderberg, E. M. V., Andersen, R., Keller, U., Ny, L., Svane, I. M., Nilsson, L. M. & Nilsson, J. A., 1 Dec 2017, In: Nature Communications. 8, 10 p., 707.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Adoptive Transfer 100%
  • mice 90%
  • tumors 62%
  • T-Lymphocytes 53%
  • Neoplasms 28%
  63 Citations (Scopus)

  63 Downloads (Pure)

• Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study

  Kongsted, P., Borch, T. H., Ellebaek, E., Iversen, T. Z., Andersen, R., Met, Ö., Hansen, M., Lindberg, H., Sengeløv, L. & Svane, I. M., 1 Apr 2017, In: Cytotherapy. 19, 4, p. 500-513 14 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Cancer Vaccines 100%
  • Docetaxel 92%
  • Castration 91%
  • Dendritic Cells 73%
  • Vaccination 66%
  28 Citations (Scopus)

• Immunterapi er kræftbehandling med en helt ny bivirkningsprofil

  Translated title of the contribution: Immunotherapy is cancer treatment with a novel side-effect profileKondrup, M., Raunkilde, L., Svane, I. M., Schmidt, H. & Bastholt, L., 2017, In: Ugeskrift for Laeger. 179, 5 p., V05170365.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Immunotherapy 100%
  • B7-H1 Antigen 59%
  • Cytotoxic T-Lymphocytes 40%
  • Neoplasms 36%
  • Anti-Idiotypic Antibodies 31%

• Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma

  Nitschke, N. J., Bjoern, J., Iversen, T. Z., Andersen, M. H. & Svane, I. M., 1 Sept 2017, In: Stem Cell Investigation. 4, 13 p., 77.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Indoleamine-Pyrrole 2,3,-Dioxygenase 100%
  • Temozolomide 91%
  • Subunit Vaccines 89%
  • Survivin 88%
  • Melanoma 61%
  11 Citations (Scopus)

• Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma

  Bjoern, J., Lyngaa, R., Andersen, R., Rosenkrantz, L. H., Hadrup, S. R., Donia, M. & Svane, I. M., 2017, In: OncoTarget. 8, 16, p. 27062-27074

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Ipilimumab 100%
  • Melanoma 59%
  • T-Lymphocytes 44%
  • Neoplasm Antigens 30%
  • Cell- and Tissue-Based Therapy 27%
  16 Citations (Scopus)

  56 Downloads (Pure)

• Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

  Ascierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., McNeil, C., Garbe, C., Loquai, C., Dreno, B., Thomas, L., Grob, J-J., Liszkay, G., Nyakas, M., Gutzmer, R., Pikiel, J., & 10 othersGrange, F., Hoeller, C., Ferraresi, V., Smylie, M., Schadendorf, D., Mortier, L., Svane, I. M., Hennicken, D., Qureshi, A. & Maio, M., May 2017, In: Lancet Oncology. 18, 5, p. 611-622 12 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Ipilimumab 100%
  • Melanoma 59%
  • Survival 10%
  • Therapeutics 7%
  • Hypophysitis 7%
  251 Citations (Scopus)

• Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

  Lauss, M., Donia, M., Harbst, K., Andersen, R., Mitra, S., Rosengren, F., Salim, M., Vallon-Christersson, J., Törngren, T., Kvist, A., Ringnér, M., Svane, I. M. & Jönsson, G., 2017, In: Nature Communications. 8, 11 p., 1738.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • therapy 100%
  • Cell- and Tissue-Based Therapy 99%
  • Biological Marker 94%
  • Mutation 88%
  • Antigen 87%
  118 Citations (Scopus)

  84 Downloads (Pure)

• PD-1⁺ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer

  Donia, M., Kjeldsen, J. W., Andersen, R., Westergaard, M. C. W., Bianchi, V., Legut, M., Attaf, M., Szomolay, B., Ott, S., Dolton, G., Lyngaa, R., Hadrup, S. R., Sewell, A. K. & Svane, I. M., 1 Oct 2017, In: Clinical Cancer Research. 23, 19, p. 5779-5788

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor-Infiltrating Lymphocytes 100%
  • T-Lymphocytes 48%
  • Neoplasms 25%
  • Therapeutics 12%
  • Phenotype 10%
  23 Citations (Scopus)

• PD-L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy

  Steiniche, T., Vestergaard Danielsen, A., Wang, Z., Feng, Y., Switten Nielsen, P., Bastholt, L., Schmidt, H., Svane, I. M., Dolled-Filhart, M., Emancipator, K., Weiner, R., Busch-Sørensen, M. & Zhou, W., Jul 2017, In: Journal of the European Academy of Dermatology and Venereology. 31, 7, p. e319-e321

  Research output: Contribution to journal › Comment/debate › Research

  3 Citations (Scopus)

• Predictors of responses to immune checkpoint blockade in advanced melanoma

  Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Ternès, N., Jegou, S., Woods, D. M., Sodré, A. L., Hansen, M., Meirow, Y., Sade-Feldman, M., Burra, A., Kwek, S. S., Flament, C., Messaoudene, M., Duong, C. P. M., Chen, L., Kwon, B. S., Anderson, A. C., Kuchroo, V. K., & 30 othersWeide, B., Aubin, F., Borg, C., Dalle, S., Beatrix, O., Ayyoub, M., Balme, B., Tomasic, G., Di Giacomo, A. M., Maio, M., Schadendorf, D., Melero, I., Dréno, B., Khammari, A., Dummer, R., Levesque, M., Koguchi, Y., Fong, L., Lotem, M., Baniyash, M., Schmidt, H., Svane, I. M., Kroemer, G., Marabelle, A., Michiels, S., Cavalcanti, A., Smyth, M. J., Weber, J. S., Eggermont, A. M. & Zitvogel, L., 1 Dec 2017, In: Nature Communications. 8, 13 p., 592.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor Marker 100%
  • Adjuvant 93%
  • Biological Marker 68%
  • Melanoma 62%
  • blood 48%
  100 Citations (Scopus)

  69 Downloads (Pure)

• Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein

  Buschow, S. I., Ramazzotti, M., Reinieren-Beeren, I. M. J., Heinzerling, L. M., Westdorp, H., Stefanini, I., Beltrame, L., Hato, S. V., Ellebaek, E., Gross, S., Nguyen, V. A., Weinlich, G., Ragoussis, J., Baban, D., Schuler-Thurner, B., Svane, I. M., Romani, N., Austyn, J. M., De Vries, I. J. M., Schuler, G., & 2 othersCavalieri, D. & Figdor, C. G., 2017, In: OncoTarget. 8, 40, p. 67439-67456 18 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Phosphatidylethanolamine Binding Protein 100%
  • Proto-Oncogene Proteins c-raf 92%
  • Dendritic Cells 53%
  • Melanoma 50%
  • Vaccination 48%
  12 Citations (Scopus)

  96 Downloads (Pure)

• The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

  Holmström, M. O., Hjortso, M. D., Ahmad, S. M., Met, O., Martinenaite, E., Riley, C., Straten, P., Svane, I. M., Hasselbalch, H. C. & Andersen, M. H., 1 Feb 2017, In: Leukemia. 31, p. 495-498

  Research output: Contribution to journal › Letter › peer-review

  30 Citations (Scopus)

• The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials

  Donia, M., Kimper-Karl, M. L., Høyer, K. L., Bastholt, L., Schmidt, H. & Svane, I. M., 1 Mar 2017, In: European Journal of Cancer. 74, p. 89-95

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Immunotherapy 100%
  • Melanoma 94%
  • Patient Selection 24%
  • Population 16%
  • Survival 15%
  43 Citations (Scopus)
• 2016

  Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21

  Hansen, M., Met, Ö., Larsen, N. B., Rosenkilde, M. M., Andersen, M. H., Svane, I. M. & Hjorto, G. M., 1 Sept 2016, In: Cytotherapy. 18, 9, p. 1187-1196

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Dendritic Cells 100%
  • Cell Movement 91%
  • Dinoprostone 22%
  • Chemotaxis 18%
  • In Vitro Techniques 10%
  9 Citations (Scopus)

• Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen

  Translated title of the contribution: Treatment of BRAF-mutated metastatic melanomaBoyles, T. B., Svane, I. M., Bastholt, L. & Schmidt, H., 2016, In: Ugeskrift for Laeger. 178, 4 p., V02160126.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Melanoma 100%
  • Mitogen-Activated Protein Kinase Kinases 87%
  • Skin Neoplasms 83%
  • Denmark 42%
  • Treatment Failure 38%

• Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer

  Kongsted, P., Svane, I. M., Lindberg, H., Bisbjerg, R., Daugaard, G. & Sengeløv, L., Aug 2016, In: Anti-Cancer Drugs. 27, 7, p. 695-701 7 p.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • cabazitaxel 100%
  • Castration 70%
  • Prostatic Neoplasms 50%
  • Prostate-Specific Antigen 19%
  • Progression-Free Survival 17%
  3 Citations (Scopus)

• CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment

  Martinenaite, E., Munir Ahmad, S., Hansen, M., Met, Ö., Westergaard, M. W., Larsen, S. K., Klausen, T. W., Donia, M., Svane, I. M. & Andersen, M. H., 2016, In: OncoImmunology. 5, 11, 10 p., e1238541.

  Research output: Contribution to journal › Journal article › Research › peer-review

  • Tumor Microenvironment 100%
  • Immunosuppressive Agents 80%
  • T-Lymphocytes 59%
  • Neoplasms 31%
  • T-Lymphocyte Epitopes 29%
  29 Citations (Scopus)